ArticleProceedings of the National Academy of Sciences of the United States of America2015
NFκB activation by modified vaccinia virus as a novel strategy to enhance neutrophil migration and HIV-specific T-cell responses.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 32 citations in OpenAlex.
- Vaccinia virus for lung cancer therapy: preclinical progress and prospects as a systemic immunotherapy platform.Frontiers in immunology · 2026Review
- Vaccinia Virus: Mechanisms Supporting Immune Evasion and Successful Long-Term Protective Immunity.Viruses · 2024Review
- Novel peptide-based oncolytic vaccine for enhancement of adaptive antitumor immune response via co-engagement of innate Fcγ and Fcα receptors.Journal for immunotherapy of cancer · 2024Article
- Neutrophils in oncolytic virus immunotherapy.Frontiers in immunology · 2024Review
- Review
- Cutting both ways: the innate immune response to oncolytic virotherapy.Cancer gene therapy · 2022Review
- Neutrophil Functional Heterogeneity and Implications for Viral Infections and Treatments.Cells · 2022Review
- Neutrophil subtypes shape HIV-specific CD8 T-cell responses after vaccinia virus infection.NPJ vaccines · 2021Article
- Determinants of Innate Immunity in Visceral Leishmaniasis and Their Implication in Vaccine Development.Frontiers in immunology · 2021Review
- Essential Role of Neutrophils in the Protective Immune Response Induced by a Live AttenuatedJournal of immunology (Baltimore, Md. : 1950) · 2020Article
- NF-κB as an Important Factor in Optimizing Poxvirus-Based Vaccines against Viral Infections.Pathogens (Basel, Switzerland) · 2020Review
- Article
- Deletion of Vaccinia Virus A40R Gene Improves the Immunogenicity of the HIV-1 Vaccine Candidate MVA-B.Vaccines · 2020Article
- Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics.Journal for immunotherapy of cancer · 2019Review
- Article
- Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.Journal of virology · 2018Article
- Development of a Safe and Effective Vaccinia Virus Oncolytic Vector WR-Δ4 with a Set of Gene Deletions on Several Viral Pathways.Molecular therapy oncolytics · 2018Article
- Interleukin 10 modulation of neutrophil subsets infiltrating lungs duringBiochemistry and biophysics reports · 2018Article
- Immune Modulation of NYVAC-Based HIV Vaccines by Combined Deletion of Viral Genes that Act on Several Signalling Pathways.Viruses · 2017Article
- Distinct Roles of Vaccinia Virus NF-κB Inhibitor Proteins A52, B15, and K7 in the Immune Response.Journal of virology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neutrophils are antigen-transporting cells that generate vaccinia virus (VACV)-specific T-cell responses, yet how VACV modulates neutrophil recruitment and its significance in the immune response are unknown. We generated an attenuated VACV strain that expresses HIV-1 clade C antigens but lacks three specific viral genes (A52R, K7R, and B15R). We found that these genes act together to inhibit the NFκB signaling pathway. Triple ablation in modified virus restored NFκB function in macrophages. After virus infection of mice, NFκB pathway activation led to expression of several cytokines/chemokines that increased the migration of neutrophil populations (Nα and Nβ) to the infection site. Nβ cells displayed features of antigen-presenting cells and activated virus-specific CD8 T cells. Enhanced neutrophil trafficking to the infection site correlated with an increased T-cell response to HIV vector-delivered antigens. These results identify a mechanism for poxvirus-induced immune response and alternatives for vaccine vector design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.